


Patented rapid Antibiotic Susceptibility Testing (AST) machine

Fast and automated AST diagnostic machine adapted to the challenges of AMR



## ANTIBIORESISTANCE

A threat to humanity



Bacteria are increasingly resistant to antibiotics – resistance levels are 0% to 82% and unpredictable

WHO 2018



Antimicrobial resistance (AMR) caused over 1 million deaths in 2019 and 10Millions deaths/years in 2050

The Lancet, 2022



Current Antimicrobial Susceptibility Testing (AST) takes 48 -72 hours – patients deteriorate whilst waiting for the correct drug



## A RAPID DIAGNOSIS

DAMOCLES reduces AST test time from 48+ to 19 hours (incl. incubation steps)



DAMOCLES is developing an in vitro diagnostic machine to help doctors and biologists reduce the turnaround time for antibiotic susceptibility testing (AST) with our innovative patented technology



A FAST AND PRODUCTIVE AUTOMATED LABORATORY DIAGNOSTIC SYSTEM


UNIT KIT / PATIENT

QUICK LOADING



# ANTIBIOTIC SUSCEPTIBILITY TESTING MARKET

## World AST market:



Projections made on data from two studies published by Market Watch & PRnewswire. Conversion €/€ = 0.91

### Total Available Market :

World market, projection to 2028

**4.1 Mrd€**

### Serviceable Available Market :

European market, projection to 2028


- Urinary Tract Infection (UTI) : 40%
- Sepsis : 30%
- MRSA : 10%
- Other : 20%

**872M€**

### Serviceable Obtainable Market :

Primary target market : UTI

Target ~10% of the global EU market : 86.1M€



## Representative market transactions

Company	Date of last ope.	Last Operation	Last funding amount	Target	Total funding amount
Resistel	2023	Series B	8,5M€	/	15.4M€
IFAST pattern	2023	Seed	2M€	/	2M€
Biomérieux	2023	Series B	23.5M€	/	49.4M€
Accelerate Diagnostics	2022	Acquisition	400M€	Specific Dx	/
Gradientech	2022	Post IPO	4M€	/	244.5M€
FastInnov	2019	Fund.	4.6M€	/	8M€
FastInnov	2016	Grant	2.7M€	/	3.1M€

## TECHNOLOGY

**Patent :** WO2021205330A1 (EU / USA / Canada)

**Maturity :** TRL5 - laboratory machine

**POC :**

- Clinical study on 100 clinical strains according to ISO20776-2
- Clinical study on 50 positive Blood culture according to ISO20776-2

## FINANCE

**Road map :**

- 2023-2025 : Industrialisation
- 2025-2026 : Qualification for CE IVD

**Current fundraising :** Seed 2M€ (1.5M€ of equity) to finance the industrialisation phase

**Aims :** Industrialisation of the machine and commercialisation for research and animal health

## BOARD



Nicolas ROUSSELET

Co-founder & CEO



Guillaume BOIS-SALVARO

Co-founder & CTO



Audrey GAUTHIER

Co-founder & Head of Platform



Gaele BEGAUD

Co-founder  
Assistant Professor (AP)



Serge BATTU

Co-founder  
Professor (P)



Olivier BARRAUD

Co-founder  
AP & Hospital Practitioners (HP)